Hansoh Pharma says osteosarcoma treatment drug meets primary endpoint in late stage trial
28/07/2026 11:18
Hansoh Pharma says osteosarcoma treatment drug meets primary endpoint in late stage trial July 28 (Reuters) - Hong Kong-listed Hansoh Pharmaceutical 3692.HK said on Tuesday that its B7-H3-directed antibody-drug conjugate, HS-20093, met the primary endpoint in a late-stage clinical trial.
The company said the drug showed a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy.
(Reporting by Nichiket Sunil in Bengaluru; Editing by Tasim Zahid)
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion